Navigation Links
Wyeth Pharmaceuticals and Catalyst Biosciences Announce Agreement to Develop and Commercialize Factor VIIa Products
Date:6/30/2009

git royalties on sales of products resulting from the collaboration.

"This collaboration serves as an excellent fit with our recombinant Factor VIII and Factor IX hemophilia products and provides us with an opportunity to expand Wyeth's hemophilia franchise," says Mikael Dolsten, President, Wyeth Research. "We have been impressed by the caliber of Catalyst's therapeutic protein engineering skills used in the Factor VIIa program and the lead candidate CB 813. We look forward to a highly productive collaboration."

"We are thrilled to join forces with Wyeth, a biopharmaceutical company at the forefront of both hemophilia treatment and the development and commercialization of biologic therapies," says Nassim Usman, Ph.D., Chief Executive Officer of Catalyst Biosciences. "This collaboration highlights the value Catalyst has created in our Factor VIIa portfolio of products. Revenues generated from research collaborations such as this one allow us to continually expand and support existing discovery efforts around bleeding disorder product candidates and the engineering of new Alterase therapeutic products."

About Catalyst Biosciences

Catalyst Biosciences is developing the next generation of biopharmaceuticals by harnessing the catalytic power of engineered proteases to target proteins underlying disease. Catalyst's discovery platform rapidly creates and optimizes tailor-made protease drug candidates that cleave a wide variety of disease targets, either by improving existing protease drugs or by creating new protease drugs, known as Alterase(TM) therapeutics. Initially, Catalyst is focusing its product development efforts on drug candidates for hemophilia, age-related macular degeneration and inflammation. To date, Catalyst has established multiple discovery research and product development agreements with Wyeth Pharmaceuticals and Centocor Research & Development, Inc. Catalyst is priva
'/>"/>

SOURCE Catalyst Biosciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine news :

1. Wyeth and Nycomed Announce Court Denial of Preliminary Injunction
2. Wyeths Pearl River, N.Y. Facility Celebrates 100 Years of Achievements in Health care
3. Wyeth Announces Election of Bernard Poussot as CEO of Company Effective January 1, 2008
4. Wyeth Announces the Election of Robert M. Amen to Its Board of Directors
5. Wyeth Comments on PREVNAR and Trends in Pneumococcal Disease
6. Wyeth to Appeal Nevada Hormone Therapy Trial Verdict
7. Wyeth Reports Earnings Results for the 2007 Third Quarter and First Nine Months
8. Wyeth Consumer Healthcare Initiates Voluntary Recall and Replacement Program for Several Robitussin Products and Childrens Dimetapp Cold & Chest Congestion
9. Wyeth Consumer Healthcare Announces the Availability of Centrum Cardio and New Formula Centrum Products
10. Wyeth to Present at the Credit Suisse First Boston Healthcare Conference
11. Wyeth Receives FDA Approval of Protonix for Delayed-Release Oral Suspension
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/18/2013)... May 18, 2013 The Communities of ... special places we call home. These are the townships, villages ... are the locations where the people are friendly and neighbors ... viewers off the highways and shares the best in both ... nations with an American sports and film celebrity. It airs ...
(Date:5/18/2013)... TheBeautyPlace.com answers important questions about the hairloss ... a result of stress, nutrient deficiency or wearing a ... of men suffer from male patterned baldness. ... hair transplant surgery, but additionally carries a hair care ... Bosley Professional Strength. Their product line is a five-step ...
(Date:5/18/2013)... Although obesity is associated with an increased ... and esophageal adenocarcinoma, a type of esophageal cancer, is ... reported on Cancer.gov, last reviewed in January 2012, ... as those of normal and healthy weight to develop ... esophageal cancer is not well understood, it is now ...
(Date:5/18/2013)... Adolescents, especially young males, who experiment with ... are landing in emergency rooms across America. ... with a new treatment program for those addicted ... from the National Institute on Drug Abuse, synthetic marijuana ... teenagers. In 2012, 11 percent of high school seniors ...
(Date:5/18/2013)... 18, 2013 Rio Salon and Spa, ... a stylish renovation that features tranquil, Eastern Asian influenced ... the ground up, this Morro Bay day spa ... soothing colors and comfortable spa beds. Additional salon stations ... Apilus epilator machine. The shampoo area has been ...
Breaking Medicine News(10 mins):Health News:Communities of Distinction TV Presents "A Place to Call Home" Segment 2Health News:TheBeautyPlace.com Features the Two New Best-Selling Hairloss Products: Bosley Professional Strength and Nioxin Systems 2Health News:TheBeautyPlace.com Features the Two New Best-Selling Hairloss Products: Bosley Professional Strength and Nioxin Systems 3Health News:hCGtreatments / Diet Doc Hcg Diets & Weight Loss Plans Announces New Prescription Hcg Diet Plans Designed to Trim Inches and Thus Reduce the Risk of Esophageal Cancer 2Health News:hCGtreatments / Diet Doc Hcg Diets & Weight Loss Plans Announces New Prescription Hcg Diet Plans Designed to Trim Inches and Thus Reduce the Risk of Esophageal Cancer 3Health News:Spice Addiction Treatment and Synthetic Marijuana Drug Rehab Announced by Recovery Associates 2Health News:Rio Salon and Spa, a Beauty Salon in Morro Bay, Undergoes Makeover 2
... Quantum Group,(Amex: QGP ) (http://www.QuantumMD.com ) ... become a third party administrator (TPA) with the ... company, Renaissance,Administrative Services, Inc. (RASI), to provide administrative ... A TPA provides an outsourced solution to ...
... low-sodium diet does not appear to have any appreciable ... new research. , "Despite the clear benefit of a ... therapeutic benefit in the use of a low-sodium dieton ... K. Pogson, M.R.C.P., clinical research fellow at the University ...
... Magnetic Resonance Imaging (MRI), and Broadlane’s clients awarded the High-Field Open ... ... Dallas, TX (PRWEB) July 15, 2008 -– Broadlane recently held ... Broadlane’s clients awarded the High-Field Open MRI contract to Hitachi Medical ...
... Obesity expert Sanford Siegal, D.O., M.D., known to generations as the ... 9th , ... McLean, VA (PRWEB) July 15, 2008 ... Dr. Siegal's® COOKIE DIET™ hunger-controlling foods and operator of seven ...
... full-day kindergarten have slightly better reading and math skills ... benefits diminish soon after the children leave kindergarten. This ... poverty and the quality of children,s home environments. , ... researchers at the University of Pittsburgh and Loyola University ...
... 14 Sun Pharmaceutical Industries,Ltd. (Reuters: SUN.BO, Bloomberg: ... its subsidiary, Alkaloida Chemical Company Exclusive Group,Ltd. (Alkaloida), ... Offer for,purchase of all outstanding Ordinary Shares of ... extended to 5:00 p.m., New York,City time, on ...
Cached Medicine News:Health News:The Quantum Group Files TPA Application 2Health News:The Quantum Group Files TPA Application 3Health News:Low-sodium advice for asthmatics should be taken with a grain of salt 2Health News:Broadlane's Live Group Buy Awards High-Field Open MRI Contract to Hitachi Medical Systems America Inc. 2Health News:Broadlane's Live Group Buy Awards High-Field Open MRI Contract to Hitachi Medical Systems America Inc. 3Health News:Broadlane's Live Group Buy Awards High-Field Open MRI Contract to Hitachi Medical Systems America Inc. 4Health News:Eighth Dr. Siegal's COOKIE DIET Retail Location Opens August 1st at Tysons Corner Center Near Washington, DC 2Health News:Eighth Dr. Siegal's COOKIE DIET Retail Location Opens August 1st at Tysons Corner Center Near Washington, DC 3Health News:Full-day kindergarteners' reading, math gains fade by 3rd grade 2Health News:Sun Pharma Extends Tender Offer for Taro 2
(Date:5/16/2013)... , May 16, 2013  PTC Therapeutics, Inc., ... on Form S-1 with the U.S. Securities and Exchange ... of its common stock. The number of shares to ... have not been determined. (Logo:  http://photos.prnewswire.com/prnh/20010919/PTCLOGO ... are acting as joint book-running managers for the offering. ...
(Date:5/16/2013)...  Today, the National Patient Advocate Foundation acknowledges that ... Representatives recently approved a bill that would prohibit insurers ... out-of-pocket fees for newer, more expensive oral anti-cancer drugs ... severe side-effects. However, the bill was amended to include ... to be a barrier to patients with cancer and ...
(Date:5/16/2013)... , May 16, 2013  Alere Inc. (NYSE: ... charge of their health at home through the merger of ... of $3.00 per share on its Series B Convertible Perpetual ... 15, 2013 to holders of record of Series B stock ... Such payment will cover the amount of all dividends ...
Breaking Medicine Technology:PTC Therapeutics, Inc. Files Registration Statement for Proposed Initial Public Offering 2National Patient Advocate Foundation Responds to N.C. State House Approval of Flawed Cancer Treatment Fairness Bill 2National Patient Advocate Foundation Responds to N.C. State House Approval of Flawed Cancer Treatment Fairness Bill 3
2 mm wide tip with 1 mm by 4 mm eye. Curved shaft and ring handle with polished finish....
Straight iris forceps. Insulated....
Hardy bayonet forceps with stops. Insulated....
Cushing forceps. Insulated....
Medicine Products: